Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.

ABSTRACT: The first-line therapy for locally advanced basal cell carcinoma (laBCC) is Hedgehog pathway inhibitors (HHIs), as they achieve good efficacy and duration of response. However, toxicity in the course of long-term treatment may lead to a decrease in the quality of life, and consequently to interruption or even discontinuation of therapy. As HHI therapy is a balancing act between effectiveness, adverse events, quality of life, and adherence, numerous successful treatment strategies have evolved, such as dose reduction and dose interruptions with on-off treatment schedules or interruptions with re-challenge after progression. As a small percentage of patients show primary or acquired resistance to HHIs, the inhibition of programmed cell death protein 1 (PD-1) has been approved as a second-lin

SUBMITTER: Heppt MV 

PROVIDER: S-EPMC9559463 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature